Multiple Myeloma News
Our physicians are frequently featured in patient education series. They present at major medical meetings, and publish extensively in peer-reviewed journals. This section includes links to some of these informative presentations and journal articles
Abstracts
American Society of Hematology (ASH), Annual Meeting 2023
- Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma
- Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients
- Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease
- Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial
- Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy
- Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma
- Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients – a Single-Center Observational Study
- Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma
- Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation
- Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
American Society of Hematology (ASH), Annual Meeting 2020
- CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
- Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate 2 or High Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
- A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
- CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study
- Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
- Identification of Potent Human Hematopoietic Stem Cells (HSCs) Using Mitochondrial Profile Towards Improving HSC Transplantation
- REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat
- PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients
- Mild Anemia As a Single Independent Predictor of Mortality in Patients with COVID-19
- Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy
- Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial
- Patient Similarity Network of Multiple Myeloma Identifies Patient Subgroups with Distinct Genetic and Clinical Features
- Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients
- 28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma
- Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab
- Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone
- Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
- Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis
- Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study
- Prevalence of Unexplained Erythrocytosis and Thrombocytosis - an Nhanes Analysis
- An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
- Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)
- Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model
- Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry
American Society of Clinical Oncology, Annual Meeting 2020
- KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.
- Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.
- ISS stage and network risk score to predict benefits of multiple myeloma treatment options.
American Society of Hematology (ASH), Annual Meeting 2018
- Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
- E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients
- MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1
- Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma
- Evaluation and Comparison of Characteristics and Outcomes Among Frontline Multiple Myeloma (FLMM) Patients with and without Stem Cell Transplant Treatment
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study
- Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry
- Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
- Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)
- Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM
- Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis
American Society of Clinical Oncology, Annual Meeting 2018
- Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry
- Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM)
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study
- Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)
- Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001
- Risk stratification of smoldering multiple myeloma (SMM): Predictive value of free light chains and group-based trajectory modeling (GBTM)
- Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry
- A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM)
- A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
- Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
American Society of Hematology (ASH), Annual Meeting 2017
- MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA
- Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine
- Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model
- Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project
- Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma
- Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
- Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect® MMpatient Registry
- Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database
- Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
- Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
- Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
American Society of Clinical Oncology, Annual Meeting 2017
- Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.
- Risk stratification of smoldering multiple myeloma (SMM): Predictive value of free light chains and group-based trajectory modeling (GBTM).
American Society of Hematology (ASH), Annual Meeting 2016
- MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins
- Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
- Mutation Burden in Multiple Myeloma Is Captured by Gene Expression Profiles
- A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification
Press Releases
-
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
November 2, 2023 -
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
September 29, 2023 -
Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials
December 12, 2022 - Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
November 04, 2022 - Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients
September 01, 2022 - Mount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
June 16, 2022 - Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma
April 06, 2022 - Model May Better Classify Multiple Myeloma and Relapse Risks
January 17, 2022 - Mount Sinai Researchers Present Encouraging Clinical Trial Results on Novel Therapy for Bone Marrow Cance
December 11, 2021 - Potentially Serious Side Effect Seen in Patient after Immunotherapy
December 10, 2021 - Scientists Identify New Types of a Blood Cancer and Potential Targeted Treatments
November 17, 2021 - Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients
June 28, 2021 - Researchers Identify Potential Formula for Blood Cancer Vaccine
December 19, 2019 - Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
August 22, 2019 - Mount Sinai Researchers Create RNA and DNA-Sequencing Platform to Match Broader Swath of Cancer Drugs to Patients With Few Options
August 08, 2018 - New Therapeutic Target in Myeloma Discovered
March 7, 2016
Publications
-
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma
EBioMedicine. 2023 Dec. PMID: 37995467 -
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
Clinical Lymphoma, Myeloma and Leukemia. 2023 Dec. PMID: 37743180 -
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Blood Cancer Discovery. 2023 Nov 1. PMID: 37769148 -
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Blood Advances. 2023 Sep 23. PMID: 37772981 -
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology. 2023 Jun. PMID: 37403937 -
Trial designs and endpoints for immune therapies in multiple myeloma
American Journal of Hematology. 2023 Mar. PMID: 36200130 -
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Blood Advances. 2023 Mar 28. PMID: 36018226 -
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Blood. 2023 Feb 1. PMID: 36327160 - Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy
Blood. 2022 Nov 3. PMID: 36327160 - High dimensional immune profiling of smoldering multiple myeloma distinguishes distinct tumor microenvironments
Clinical Lymphoma, Myeloma and Leukemia. 2022 Jul 16. PMID: 35945129 - Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients
Blood Advances. 2022 Aug 27. PMID: 36018226 - Signature predicts response to selinexor in multiple myeloma
JCO Precision Oncology. 2022 Jun 6. PMID: 3570479 - Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Cancer Cell. 2022 Apr 6. PMID: 35390296 - Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens
Journal for Immunotherapy of Cancer. 2022 Feb. PMID: 35190376 - Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
Cancer Medicine. 2022 Jan. PMID: 34921527 - Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Nature Medicine. 2021 December. PMID: 34893771 - Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Science Advances. 2021 Nov 17. PMID: 34788103 - Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Cancer Cell. 2021 Oct 18. PMID: 34706273 - Bispecific Antibodies in Multiple Myeloma: Present and Future
Blood Cancer Discovery. 2021 Sep. PMID: 34661161 - Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Cancer Cell. 2021 Jun 29. PMID: 34242572 - Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Lancet. 2021 Jun 24. PMID: 34175021 - KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal. 2021 Jun 18. PMID: 34145225 - Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology. 2021 Jun 1. PMID: 34062004 - Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica. 2021 Jun 1. PMID: 32354874 - Selinexor for the treatment of patients with previously treated multiple myeloma
Expert Review of Hematology. 2021 May 14. PMID: 33985401 - Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
Annals of Hematology. 2021 May 10. PMID: 33970288 - Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Cancer. 2021 Mar 18. PMID: 33735504 - The management of patients with difficult-to-treat multiple myeloma
Future Oncology. 2021 Mar 12. PMID: 33706558 - Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report
Journal of Medical Case Reports. 2021 Feb 19. PMID: 33608053 - Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2021 Feb 7. PMID: 33716054 - Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA
Future Oncology. 2021 Feb. PMID: 33522834 - A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Expert Reviews of Hematology. 2021 Jan. PMID: 33331794 - Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Blood. 2020 Dec 24. PMID: 33367546 - Bispecifics, trispecifics, and other novel immune treatments in myeloma
Hematology, American Society of Hematology, Education Program. 2020 Dec 4. PMID: 33275733 - Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
Annals of Hematology. 2020 Oct 2. PMID: 33009581 - Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
British Journal of Haematology. 2020 Jul 30. - A tertiary center experience of multiple myeloma patients with COVID-19: lessons earned and the path forward
Journal of Hematology & Oncology. 2020 Jul 14. PMID: 32664919 - Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
Expert Review of Hematology. 2020 Mar 9. PMID: 32148109 - Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
American Journal of Hematology. 2019 Dec 8. PMID: 31814152 - Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Clinical Cancer Research. 2019 Dec 19. PMID: 31857430 - Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
New England Journal of Medicine. 2019 Aug 22. PMID: 31422920 - SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents
Clinical Lymphoma, Myeloma & Leukemia. 2019 Sep. PMID: 31427259 - Daratumumab Plus Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Blood. 2019 May 21. PMID: 31113777 - Indatuximab Ravtansine (BT062) Monotherapy in Patients with Relapsed and/or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia 2019 Feb 21. PMID: 30930134 - Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis
Clinical Lymphoma, Myeloma & Leukemia. 2019 Jan 19. PMID: 30878315 - Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies
Cancer Journal 2019 Jan/Feb. PMID: 30694857 - Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2018 Nov. PMID: 30187199 - Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Blood Advances. 2018 Jul 10. PMID: 29986853 - Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity
Advances in Experimental Medicine and Biology. 2018. PMID: 30411265 - Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
Blood Advances. 2018 Jul 10. PMID: 2991494 - Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
JCO Precision Oncology. 2018 Aug 8. PMID: 30706044 - Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling
Blood Advances. 2018 Jun 26. PMID: 29945937 - Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat
Future Oncology. 2018 May 30. PMID: 29846095 - Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Leukemia & Lymphoma. 2018 Apr 4. PMID: 29616843 - Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Clinical Lymphoma, Myeloma & Leukemia. 2018 Feb. PMID: 29395837 - The effect of novel therapies in high-molecular-risk multiple myeloma
Clinical Advances in Hematology & Oncology. 2017 Nov. PMID: 29200420 - Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia. 2017 Sep 19. PMID: 29054515 - Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Blood. 2017 Aug 24. PMID: 28637662 - Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents
Bone Marrow Transplant. 2017 Jul 24. PMID: 28737774 - Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
Leukemia. 2017 Jun 23. PMID: 28642592 - A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma
Cancer. 2016 Nov 15. PMID: 27433944 - Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
Leukemia & Lymphoma. 2016 Nov. PMID: 26943456 - A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma
British Journal of Haematology. 2016 Oct 7. PMID: 27714761 - A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
British Journal Haematology. 2016 Sept. PMID: 27196567 - Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
Expert Review of Hematology. 2016 Jul. PMID: 27291638 - Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Blood. 2016 May 26. PMID: 26932802 - Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma
Cancer Research. 2016 Mar 1. PMID: 2687384 - The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
Cancer Medicine. 2016 Mar. PMID: 26799254 - Pharmacokinetics and safety of elotuzumab combined with lenalidomide and Dexamethasone in Patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study
Clinical Lymphoma, Myeloma & Leukemia. 2016 Mar. PMID: 26795075 - Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Lancet Haematology. 2015 Dec. PMID: 26686406 - Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Expert Review of Hematology. 2016 Jan. PMID: 26558304 - Serum free light chain assessment early after stem cell transplantation as a prognostic factor in multiple myeloma
Clinical Lymphoma, Myeloma & Leukemia. 2015 Sept. PMID: 26119495 - Asymptomatic monoclonal gammopathies
Clinical Lymphoma, Myeloma & Leukemia. 2014 Sept. PMID: 25486961 - Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens
American Journal of Hematology. 2014 Jun. PMID: 24616227 - Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies
Clinical Advances in Hematology & Oncology. 2013. PMID: 24518521 - Risk stratification in multiple myeloma, part 1: characterization of high-risk disease
Clinical Advances in Hematology & Oncology. 2013 Aug. PMID: 24518420